NAVELIEVA 50MG ( Vinorelbine Injection IP 50mg )

NAVELIEVA 50 mg contains Vinorelbine, a semi-synthetic vinca alkaloid. It inhibits microtubule assembly by binding to tubulin, thereby arresting cell division in the M phase of the cell cycle. It is primarily used in lung and breast cancers.

Vinorelbine is indicated for:

1. Non-Small Cell Lung Cancer (NSCLC)
    – As monotherapy or in combination (e.g., with cisplatin)

2. Metastatic Breast Cancer

Common side effects:

•  Myelosuppression (especially neutropenia)

•  Nausea, vomiting

•  Fatigue

•  Constipation

Other side effects:

•  Alopecia (mild)

•  Injection site reactions

Serious side effects:

•  Severe neutropenia → infections

•  Peripheral neuropathy (less than other vinca alkaloids)

•  Extravasation injury

 Monitor CBC before each dose.

Dosage is based on body surface area (BSA).

Typical dosing:

•  25–30 mg/m² IV

•  Administered once weekly

50 mg vial is commonly used for adult dosing.

NOTE: This medicine should be taken only under a doctor’s supervision.